EuroSIDA Newsletter  

December 2012

Eurosida logo

EuroSIDA at HIV in Glasgow
EuroSIDA was nicely presented at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow in November 2012. All the five abstracts submitted to the conference were accepted as oral presentations:
1. Temporal Changes and regional Differences in Treatment Uptake of hepatitis C Therapy in EuroSIDA presentation
2. Increase in acute HCV incidence across Europe presentation
3. CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current ART use presentation
4. Immuno-virological discordance is associated with higher frequency of fatal and non-fatal AIDS and non-AIDS presentation
5. Advanced chronic kidney disease, end-stage renal disease and renal death in HIV-positive individuals in Europe presentation

EuroSIDA Investigators meeting during Glasgow
Thank you to all EuroSIDA Investigators who participated at the Investigators meeting on 14 November 2012 during the Glasgow conference. Attached to this Newsletter, please find the Minutes and the presentation from this meeting.

Update of EuroSIDA Study Group
In EuroSIDA we are currently updating the Study Group list. Attached to this Newsletter, you will find the Study Group document. Please check if the data regarding your EuroSIDA centre is correct. If your centre data needs to be updated, please contact Jorunn at

EuroSIDA Plasma samples
Plasma samples are collected every 6th month as an essential part of the EuroSIDA study. These plasma samples are increasingly important for the study. EuroSIDA centres that do not collect plasma samples will soon receive an e-mail where the possibilities of starting collecting these samples will be discussed. Please ensure that the collection of plasma samples is mentions in your Ethical approval for your centre´s participation in the EuroSIDA study.

Updated EuroSIDA documents
he EuroSIDA Protocol has recently been updated to version 2.0. This Protocol (and an updated Manual of Operations) will be sent out with the Follow up forms for dataset 37. Please file these two study documents in your EuroSIDA Study Binder. For some centres an updated Protocol may request an updated Ethical approval, please check with your local Ethical committee if this will be requested. Please note that due to new EU regulations, it is now possible in many EU countries to obtain a common ES approval for all centres within the same country.

Latest Publications
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. K Petoumenos, SW Worm, E Fontas, R Weber, S De Wit, M Bruyand, P Reiss, W El-Sadr, A d'Arminio Monforte, N Friis-Möller, JD Lundgren, MG Law on behalf of the D:A:D Study Group. Journal of the International AIDS Society 2012, 15:17426 article

Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. D Podlekareva, J Reekie, A Mocroft, M Losso, A Rakhmanova, E Bakowska, IA Karpov, J Lazarus, J Gatell, JD Lundgren, O Kirk. BMC Infect Dis. 2012 Sep 25;12(1):229 article

In Press:
3 Health care index score and risk of death following TB diagnosis in HIV-positive patients. DN Podlekareva, D Grint, FA Post, A Mocroft, AM Panteleev, RF Miller, JM Miro, M Bruyand, H Furrer, V Riekstina, E Girardi, MH Losso, JA Caylá, EA Malashenkov, N Obel, AM Skrahina, JD Lundgren, O Kirk and the HIV/TB study group.IJTLD In Press

CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. A Mocroft, A Phillips, J Gatell, A Horban, B Ledergerber. K Zilmer, D Jevtovic, F Maltez, O Kirk, J Lundgren. AIDS. In press

The VACS Index: An internationally generalizable risk index for mortality after one year of antiretroviral therapy. JP Tate, AC Justice, MD Hughes, F Bonnet, P Reiss, A Mocroft, J Nattermann, FC Lampe, HC Bucher, TR Sterling, HM Crane, MM Kitahata, M May, J Sterne. AIDS. 2012 Nov 6 [Epub ahead of print].

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and N. America 2002-2009. S Abgrall on behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC). AIDS. 2012 Nov 28 [Epub ahead of print].

Total number of EuroSIDA publications as of December 2012: 171
Follow-up forms for dataset 37
The FU forms for dataset 37 are currently being sent out to all EuroSIDA centres. Deadline for returning the forms is 1st February 2013. If you have questions to the shipment of the forms, please contact Jette

EuroSIDA at CROI 2013
Two EuroSIDA abstracts have been accepted as Posters for CROI in Atlanta in March 2013. More information regarding these presentations will follow.

Season´s Greetings
EuroSIDA wishes to thank everybody for their great contribution to the study in 2012 and is looking forward to our collaboration in 2013. Happy Holidays to everybody!

Update from EuroCoord
Please find the latest EuroCoord

newsletter at